William J Gradishar MD ABRCC

    Clinical Researchers Showcase Series - September 2016

    Translational Medicine Research:

 View from the Trenches Newsletter


Brought to you by:

Criterium Logo Alt Tag Line w Globe Banner 2

Translational science is motivated by the need to provide effective treatments to the right patients at the right doses for a specific disease indication). The term is used mostly in the health sciences and refers to real-time translation of bench science, conducted

only in a lab, to bedside clinical practice or dissemination

to population-based community interventions.

-  Source: NIH -- Read more

from the
Academic Breast Cancer Consortium

ABRCC Researcher Spotlight:

MEET Dr. William J. Gradishar, MD FASCO FACP
Northwestern University, Chicago, IL

ABRCC Investigator

Dr. William J. Gradishar, M.D., F.A.C.P., in addition to being Deputy Chief, Division of Hematology/Oncology Northwestern University Feinberg School of Medicine is also the Betsy Bramsen Professor of Breast Oncology & Professor of Medicine; Deputy Director, Clinical Network; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and Director, Maggie Daley Center for Women's Cancer Care.

Dr Gradishar's research focuses on the development of the latest therapies for breast cancer treatment. He has published numerous articles in the area of breast cancer therapy, with a focus on new endocrine therapy and chemotherapy.

After receiving his medical degree from the University of Illinois Abraham School of Medicine in Chicago, he completed a residency and chief residency in internal medicine at Michael Reese Hospital and Medical Center in Chicago. He then went on to a fellowship in medical oncology at the University of Chicago. He is Board Certified in Internal Medicine, Medical Oncology.

See Dr Gradishar at the BCRF Site

In addition, he is a Fellow of the American College of Physicians, a member of the American Association for Cancer Research and the American Federation for Clinical Research. He chairs the Oncology Training Program Committee of the American Society of Clinical Oncology (ASCO) and serves on numerous breast cancer committees in other major oncology organizations. In addition, he serves as a consultant to the Oncology Drug Advisory Committee of the FDA.


About Northwestern University, Chicago, IL

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota.  After completing its first building in 1855, Northwestern began classes that fall with two faculty members and 10 students. Sixteen presidents have presided over Northwestern in the years since. The University has grown to include 12 schools and colleges, with additional campuses in Chicago and Doha, Qatar. Learn more at  www.northwestern.edu


for Translational Research

The important conceptual difference between the two predominant research group approaches used today (a Clinical Trials Group vs. Consortia) is seen in this consortia model.  With its highly experienced clinical scientists, ABRCC becomes involved on an intellectual advisory level with every step of clinical investigation in a breast cancer study. Classical clinical trials groups "just run the study" with the main substantive role being patient accrual.


To read more on ABRCC and the details of why the consortia model creates fast results, please visit our website.

The Oncology Consortia of Criterium

The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:

  • AGICC:  Academic GI Cancer Consortium
  • AMyC:  Academic Myeloma Consortium
  • ATOMIC:  Academic Thoracic Oncology Medical Investigators Consortium
  • ABRCC:  Academic Breast Cancer Consortium

ABRCC Cube FULL Logo 2

Read more about Criterium Inc Global CRO

and The Oncology Consortia of Criterium on our website